What 8 Analyst Ratings Have To Say About Surgery Partners
Portfolio Pulse from Benzinga Insights
Analysts have varied opinions on Surgery Partners (NASDAQ:SGRY), with recent ratings showing a mix of bullish and somewhat bullish sentiments. The average 12-month price target has decreased by 4.28% to $42.25. Surgery Partners has shown strong revenue growth but struggles with profitability, as indicated by a negative net margin.
August 19, 2024 | 9:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Surgery Partners (SGRY) has received mixed analyst ratings, with a decrease in the average price target to $42.25. The company shows strong revenue growth but faces profitability challenges.
The mixed analyst ratings and decrease in average price target suggest a neutral short-term impact on SGRY's stock price. While the company shows strong revenue growth, its profitability challenges may offset positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100